Hematology Reports最新文献

{"title":"Managing Relevant Clinical Conditions of Hemophilia A/B Patients.","authors":"Massimo Morfini, Jacopo Agnelli Giacchiello, Erminia Baldacci, Christian Carulli, Giancarlo Castaman, Anna Chiara Giuffrida, Giuseppe Malcangi, Angiola Rocino, Sergio Siragusa, Ezio Zanon","doi":"10.3390/hematolrep15020039","DOIUrl":"10.3390/hematolrep15020039","url":null,"abstract":"<p><p>The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to the replacement therapy needed for surgery using continuous infusion (CI) versus bolus injection (BI) of standard and extended half-life Factor VIII (FVIII) concentrates in severe hemophilia A patients. Among the side effects, the risk of development of neutralizing antibodies (inhibitors) and thromboembolic complications was addressed. The specific needs of mild hemophilia A patients were described, as well as the usage of bypassing agents to treat patients with high-responding inhibitors. Young hemophilia A patients may take significant advantages from primary prophylaxis three times or twice weekly, even with standard half-life (SHL) rFVIII concentrates. Patients affected by severe hemophilia B probably have a less severe clinical phenotype than severe hemophilia A patients, and in about 30% of cases may undergo weekly prophylaxis with an rFIX SHL concentrate. The prevalence of missense mutations in 55% of severe hemophilia B patients allows the synthesis of a partially changed FIX molecule that can play some hemostatic role at the level of endothelial cells or the subendothelial matrix. The flow back of infused rFIX from the extravascular to the plasma compartment allows a very long half-life of about 30 h in some hemophilia B patients. Once weekly, prophylaxis can assure a superior quality of life in a large severe or moderate hemophilia B population. According to the Italian registry of surgery, hemophilia B patients undergo joint replacement by arthroplasty less frequently than hemophilia A patients. Finally, the relationships between FVIII/IX genotypes and the pharmacokinetics of clotting factor concentrates have been investigated.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"384-397"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9718084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms.","authors":"Orly Leiva,&nbsp;Andrew Jenkins,&nbsp;Rachel P Rosovsky,&nbsp;Rebecca K Leaf,&nbsp;Katayoon Goodarzi,&nbsp;Gabriela Hobbs","doi":"10.3390/hematolrep15020040","DOIUrl":"https://doi.org/10.3390/hematolrep15020040","url":null,"abstract":"<p><p>Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors for all-cause death or CV events post-ACS hospitalization are lacking. We conducted a single-center study of 41 consecutive patients with MPN with ACS hospitalization after MPN diagnosis. After a median follow-up of 80 months after ACS hospitalization, 31 (76%) experienced death or a CV event (myocardial infarction, ischemic stroke, or heart failure hospitalization). After multivariable Cox proportional hazards regression, index ACS within 12 months of MPN diagnosis (HR 3.84, 95% CI 1.44-10.19), WBC ≥ 20 K/µL (HR 9.10, 95% CI 2.71-30.52), <i>JAK2</i> mutation (HR 3.71, 95% CI 1.22-11.22), and prior CVD (HR 2.60, 95% CI 1.12-6.08) were associated with increased death or CV events. Further studies are warranted to improve cardiovascular outcomes in this patient population.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"398-404"},"PeriodicalIF":0.9,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic Rupture Secondary to Amyloidosis: A Case Report and Review of the Literature.","authors":"Hisham F Bahmad,&nbsp;Samantha Gogola,&nbsp;Lorena Burton,&nbsp;Ferial Alloush,&nbsp;Mike Cusnir,&nbsp;Michael Schwartz,&nbsp;Lydia Howard,&nbsp;Vathany Sriganeshan","doi":"10.3390/hematolrep15020038","DOIUrl":"https://doi.org/10.3390/hematolrep15020038","url":null,"abstract":"<p><p>Amyloidosis is a term describing the extracellular deposit of fibrils composed of subunits of several different normal serum proteins in various tissues. Amyloid light chain (AL) amyloidosis contains fibrils that are composed of fragments of monoclonal light chains. Many different disorders and conditions can lead to spontaneous splenic rupture, including AL amyloidosis. We present a case of a 64-year-old woman with spontaneous splenic rupture and hemorrhage. A final diagnosis of systemic amyloidosis secondary to plasma cell myeloma was made with infiltrative cardiomyopathy and possible diastolic congestive heart failure exacerbation. We also provide a narrative review of all documented cases of splenic rupture associated with amyloidosis from the year 2000 until January 2023, along with the main clinical findings and management strategies.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"370-383"},"PeriodicalIF":0.9,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Therapeutic Anticoagulation in COVID-19: The Current Situation.","authors":"Mandeep Singh Rahi,&nbsp;Jay Parekh,&nbsp;Prachi Pednekar,&nbsp;Mayuri Mudgal,&nbsp;Vishal Jindal,&nbsp;Kulothungan Gunasekaran","doi":"10.3390/hematolrep15020037","DOIUrl":"https://doi.org/10.3390/hematolrep15020037","url":null,"abstract":"<p><p>Thrombotic complications from COVID-19 are now well known and contribute to significant morbidity and mortality. Different variants confer varying risks of thrombotic complications. Heparin has anti-inflammatory and antiviral effects. Due to its non-anticoagulant effects, escalated-dose anticoagulation, especially therapeutic-dose heparin, has been studied for thromboprophylaxis in hospitalized patients with COVID-19. Few randomized, controlled trials have examined the role of therapeutic anticoagulation in moderately to severely ill patients with COVID-19. Most of these patients had elevated D-dimers and low bleeding risks. Some trials used an innovative adaptive multiplatform with Bayesian analysis to answer this critical question promptly. All the trials were open-label and had several limitations. Most trials showed improvements in the meaningful clinical outcomes of organ-support-free days and reductions in thrombotic events, mainly in non-critically-ill COVID-19 patients. However, the mortality benefit needed to be more consistent. A recent meta-analysis confirmed the results. Multiple centers initially adopted intermediate-dose thromboprophylaxis, but the studies failed to show meaningful benefits. Given the new evidence, significant societies have suggested therapeutic anticoagulation in carefully selected patients who are moderately ill and do not require an intensive-care-unit level of care. There are multiple ongoing trials globally to further our understanding of therapeutic-dose thromboprophylaxis in hospitalized patients with COVID-19. In this review, we aim to summarize the current evidence regarding the use of anticoagulation in patients with COVID-19 infection.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"358-369"},"PeriodicalIF":0.9,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiology of Anemia and Risk Factors of Mortality among Hospitalized Patients: A Real-Life Retrospective Study in a Tertiary Center in Greece.","authors":"Petros Ioannou,&nbsp;Andria Papazachariou,&nbsp;Maria Tsafaridou,&nbsp;Ioannis E Koutroubakis,&nbsp;Diamantis P Kofteridis","doi":"10.3390/hematolrep15020036","DOIUrl":"https://doi.org/10.3390/hematolrep15020036","url":null,"abstract":"<p><p>Anemia is a prominent global health issue with a wide variety of causes and can be associated with decreased quality of life, increased hospitalization, and higher mortality, especially in older individuals. Therefore, studies further shedding light on the causes and the risk factors of this condition should be performed. The aim of the present study was to examine the causes of anemia in hospitalized patients in a tertiary hospital in Greece and identify risk factors related to higher mortality. In total, 846 adult patients with a diagnosis of anemia were admitted during the study period. The median age was 81 years, and 44.8% were male. The majority of patients had microcytic anemia, with the median mean corpuscular volume (MCV) being 76.3 fL and the median hemoglobin being 7.1 g/dL. Antiplatelets were used by 28.6% of patients, while 28.4% were using anticoagulants at the time of diagnosis. At least one unit of packed red blood cells (PRBCs) was transfused in 84.6% of patients, and a median of two PRBCs was used per patient. A gastroscopy was performed in 55%, and a colonoscopy was performed in 39.8% of patients in the present cohort. Anemia was considered to be multifactorial in almost half the cases, while the most commonly identified cause was iron deficiency anemia, more commonly with positive endoscopic findings. Mortality was relatively low, at 4.1%. Multivariate logistic regression analysis identified higher B12 levels and longer duration of hospital stay to be independently positively associated with mortality.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"347-357"},"PeriodicalIF":0.9,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.","authors":"Shinichiro Takahashi","doi":"10.3390/hematolrep15020035","DOIUrl":"https://doi.org/10.3390/hematolrep15020035","url":null,"abstract":"<p><p>Targeting kinase activity is considered to be an attractive therapeutic strategy to overcome acute myeloid leukemia (AML) since aberrant activation of the kinase pathway plays a pivotal role in leukemogenesis through abnormal cell proliferation and differentiation block. Although clinical trials for kinase modulators as single agents remain scarce, combination therapies are an area of therapeutic interest. In this review, the author summarizes attractive kinase pathways for therapeutic targets and the combination strategies for these pathways. Specifically, the review focuses on combination therapies targeting the FLT3 pathways, as well as PI3K/AKT/mTOR, CDK and CHK1 pathways. From a literature review, combination therapies with the kinase inhibitors appear more promising than monotherapies with individual agents. Therefore, the development of efficient combination therapies with kinase inhibitors may result in effective therapeutic strategies for AML.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"331-346"},"PeriodicalIF":0.9,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9716610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenazopyridine-Induced Methemoglobinemia in a Jehovah's Witness Treated with High-Dose Ascorbic Acid Due to Methylene Blue Contradictions: A Case Report and Review of the Literature.","authors":"Sasmith R Menakuru,&nbsp;Vijaypal S Dhillon,&nbsp;Mona Atta,&nbsp;Keeret Mann,&nbsp;Ahmed Salih","doi":"10.3390/hematolrep15020034","DOIUrl":"https://doi.org/10.3390/hematolrep15020034","url":null,"abstract":"<p><p>Methemoglobinemia is an acute medical emergency that requires prompt correction. Physicians should have a high degree of suspicion of methemoglobinemia in cases that present with hypoxemia that does not resolve with supplemental oxygenation, and they should confirm this suspicion with a positive methemoglobin concentration on arterial blood gas. There are multiple medications that can induce methemoglobinemia, such as local anesthetics, antimalarials, and dapsone. Phenazopyridine is an azo dye used over-the-counter as a urinary analgesic for women with urinary tract infections, and it has also been implicated in causing methemoglobinemia. The preferred treatment of methemoglobinemia is methylene blue, but its use is contraindicated for patients with glucose-6-phosphatase deficiency or those who take serotonergic drugs. Alternative treatments include high-dose ascorbic acid, exchange transfusion therapy, and hyperbaric oxygenation. The authors report a case of a 39-year-old female who took phenazopyridine for 2 weeks to treat dysuria from a urinary tract infection and subsequently developed methemoglobinemia. The patient had contraindications for the use of methylene blue and was therefore treated with high-dose ascorbic acid. The authors hope that this interesting case promotes further research into the utilization of high-dose ascorbic acid for managing methemoglobinemia in patients who are unable to receive methylene blue.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"325-330"},"PeriodicalIF":0.9,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the <i>MPL</i> Gene: Two Case Reports.","authors":"Maria Stella Pennisi,&nbsp;Sandra Di Gregorio,&nbsp;Elena Tirrò,&nbsp;Chiara Romano,&nbsp;Andrea Duminuco,&nbsp;Bruno Garibaldi,&nbsp;Gaetano Giuffrida,&nbsp;Livia Manzella,&nbsp;Paolo Vigneri,&nbsp;Giuseppe A Palumbo","doi":"10.3390/hematolrep15020033","DOIUrl":"https://doi.org/10.3390/hematolrep15020033","url":null,"abstract":"<p><p>Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are two of the main <i>BCR-ABL1</i>-negative chronic myeloproliferative neoplasms (MPNs) characterized by abnormal megakaryocytic proliferation. <i>Janus kinase 2</i> (<i>JAK2</i>) mutations are detected in 50-60% of ET and PMF, while <i>myeloproliferative leukemia</i> (<i>MPL</i>) virus oncogene mutations are present in 3-5% of cases. While Sanger sequencing is a valuable diagnostic tool to discriminate the most common MPN mutations, next-generation sequencing (NGS) is a more sensitive technology that also identifies concurrent genetic alterations. In this report, we describe two MPN patients with simultaneous double <i>MPL</i> mutations: a woman with ET presenting both <i>MPL</i>^V501A-W515R and <i>JAK2</i>^V617F mutations and a man with PMF displaying an uncommon double <i>MPL</i>^V501A-W515L. Using colony-forming assays and NGS analyses, we define the origin and mutational landscape of these two unusual malignancies and uncover further gene alterations that may contribute to the pathogenesis of ET and PMF.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"317-324"},"PeriodicalIF":0.9,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9716605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Factor X Deficiency without Amyloidosis Presenting with Massive Hematuria: A Case Report and Review of the Literature.","authors":"Sasmith R Menakuru,&nbsp;Vijaypal S Dhillon,&nbsp;Ahmed Salih,&nbsp;Amir F Beirat","doi":"10.3390/hematolrep15020032","DOIUrl":"https://doi.org/10.3390/hematolrep15020032","url":null,"abstract":"<p><p>Acquired factor X deficiency is a rare diagnosis, especially without the association of other co-existing conditions such as amyloidosis. The authors report the case of a 34-year-old male with severe frank hematuria found to have markedly prolonged prothrombin time and activated partial thromboplastin time. A mixing study showed correction utilizing normal plasma and a coagulation panel testing revealed decreased factor X activity. The patient was treated with multiple blood transfusions, fresh frozen plasma, high-dose pulse steroids, and rituximab. The patient's condition improved during his 21-day hospital stay and was followed up every 2 weeks for 3 months. The patient's factor X level recovered after two weeks of discharge with no other hemorrhagic episodes.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"312-316"},"PeriodicalIF":0.9,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9516141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State.","authors":"Gehad Elgabry,&nbsp;Lydia Spencer,&nbsp;Hisam Siddiqi,&nbsp;Soumya Ojha,&nbsp;Farooq Wandroo","doi":"10.3390/hematolrep15020031","DOIUrl":"https://doi.org/10.3390/hematolrep15020031","url":null,"abstract":"<p><p>Multiple myeloma is a plasma cell malignancy that is most commonly observed in males in the sixth and seventh decade of life. The clinical scenario of multiple myeloma with concurrent pregnancy is considered to be very rare. We detail here the case of a young female with known IgG kappa multiple myeloma who was found to have a steady elevation of her IgG kappa paraprotein during pregnancy and symptomatic progression in the postpartum period. She delivered a healthy baby at 40 weeks gestation. We present a review of all reported cases of known multiple myeloma progressing during pregnancy and in the postpartum period, the treatments given, and their outcomes. The report also provides suggestions for diagnosis and management of myeloma during pregnancy in order to have an outcome of successful uncomplicated pregnancy with healthy offspring.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"305-311"},"PeriodicalIF":0.9,"publicationDate":"2023-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}